DENVER — The 10th Circuit reversed a ruling in favor of biotech company Genentech in a dispute over the breast cancer drug Herceptin. Cancer treatment providers who purchased multidose vials of the drug claim the company failed to ensure each vial contained the labeled amount of the active ingredient.
- Fifth Time’s a Charm? Government Wants Another Bundy Trial
- Car Display Screens